Cancer Cell's Weak Points: Designing Better Drug Combinations
Author Information
Author(s): Gahramanov Valid, Vizeacoumar Frederick S., Morales Alain Morejon, Bonham Keith, Sakharkar Meena K., Kumar Santosh, Vizeacoumar Franco J., Freywald Andrew, Sherman Michael Y.
Primary Institution: Yale University
Hypothesis
Targeting specific pathways in cancer cells can make them more sensitive to various anti-cancer drugs.
Conclusion
Inhibitors of certain pathways can enhance the effectiveness of a wide range of cancer treatments.
Supporting Evidence
- Loss of function screens identified pathways that affect responses to multiple drugs.
- Pathways like proteasome and Akt-mTOR are considered 'weak points' in cancer cells.
- Inhibitors of these pathways can sensitize cancer cells to a variety of drugs.
- Quantitative evaluations showed that targeting 'weak points' leads to higher drug diversity.
- Previous studies indicated that certain pathways are crucial for cancer cell survival.
- Partial suppression of these pathways enhances sensitivity to various therapeutic compounds.
- Data from multiple shRNA screens supported the hypothesis of 'weak points' pathways.
- Synergistic effects were observed with inhibitors of the identified pathways.
Takeaway
Some parts of cancer cells are like weak spots; if we poke them just right, the cancer can be hurt by more medicines.
Methodology
The study used loss of function screens with shRNA and CRISPR to identify pathways affecting drug responses in cancer cells.
Potential Biases
Potential biases include investigator biases in drug selection and the novelty of tested therapeutics.
Limitations
The study may be limited by biases in the selection of drug combinations and the novelty of some therapeutic targets.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website